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It is well known that glomerular podocyte injury and loss are present in numerous nephropathies and that the pathophysiologic
consecution of disease hinges upon the fate of the podocyte. While multiple factors play a hand in glomerulopathy progression,
basic logic lends that if one monitors the podocyte’s status, that may reflect the status of disease. Recent investigations have focused
on what one can elucidate from the noninvasive collection of urine, and have proven that certain, specific biomarkers of podocytes
can be readily identified via varying techniques. This paper has brought together all described urinary biomarkers of podocyte
injury and is made to provide a concise summary of their utility and testing in laboratory and clinical theatres. While promising
in the potential that they hold as tools for clinicians and investigators, the described biomarkers require further comprehensive
vetting in the form of larger clinical trials and studies that would give their value true weight. These urinary biomarkers are put
forth as novel indicators of glomerular disease presence, disease progression, and therapeutic efficacy that in some cases may be
more advantageous than the established parameters/measures currently used in practice.
1. Introduction
The glomerulus is the functional unit of the kidney that
creates from the afferent blood flow an ultrafiltrate, which
passes through the remainder of the nephron for further
modification. The glomerulus can be compared to a selective
filter in that it discerns based on size and charge what passes
on through to become the formed ultrafiltrate.This selectivity
is intrinsic to the glomerular filtration apparatus and is dic-
tated by the structural integrity of the threemain components
of which it ismade: the capillary endothelium, the glomerular
basement membrane (GBM), and the visceral epithelium
overlying the GBM. Material that navigates through the
glomerular filter must pass through these three components
in that order to attain passage from the vascular capillary
side into Bowman’s space. The visceral epithelial layer of the
glomerulus ismade up of podocytes: terminally differentiated
cells that have formed foot processes that encircle the GBM.
The foot processes interdigitate between one another, with the
space between each laying the slit diaphragm: described as a
zipper-like interaction of membrane proteins between adja-
cent podocyte foot processes [1]. The slit diaphragm is con-
sidered to be the size limiting component of the glomerular
filtration apparatus: permittingmaterial approximately under
the size of albumin, while limiting the passage of molecules
the size of serum albumin—70 kilodaltons (kDa)—and larger
[2]. The visceral epithelial layer is continuous with the
parietal epithelial layer—the layer that constitutes Bowman’s
capsule—and there are phenotypic characteristics displayed
by the two that allow for differentiation [3, 4]. A novel concept
poses that there may be additional layers to designate within
the glomerular filtration apparatus: an endothelial surface
layer and a subpodocyte space, which gives new insight
on the generally accepted structure of the glomerulus [5].
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Further, more detailed discussion of the components of the
glomerulus will be limited in this paper; however, there are
numerous reviews that pour over the details of each [6–17].
As described before, the visceral epithelial layer of the
glomerulus is made up of podocytes. The podocyte cell itself
is comprised of a cell body, major processes which are large
projections from the cell body, and long foot processes that
adhere to the GBM. Three surfaces of a foot process can be
described as apical, lateral, and basal, and while each surface
is characterized by distinctive functional and structural roles,
they are intertwined through intracellular associations. The
apical surface faces Bowman’s space, and with anionic surface
proteins such as podocalyxin and podoplanin localized on
the podocyte cell membrane, it is partially responsible for the
repulsion of anionic molecules passing through the glomeru-
lar filtration apparatus [18–20]. Also on the apical membrane
there is a protein tyrosine kinase phosphatase receptor named
glomerular epithelial protein 1 (GLEPP-1), which is noted to
regulate podocyte structure and function [21]. This negative
charge lining the membrane surface of podocytes is also con-
sidered to be responsible for the maintenance of separation
between adjacent foot processes [22]. The lateral surface of
the foot process is comprised of the slit diaphragm, which is
made up of many proteins, most notably the transmembrane
protein nephrin that has numerous intracellular associations
with both structural and signaling roles for the podocyte
[23]. In mature podocytes, the slit diaphragm is also the only
interaction between adjacent foot processes, and loss of this
normal cell-cell interaction can be noted in the diseased state
[9].The basal surface of the podocyte foot process is attached
to the GBM by the way of integrins, dystroglycans, and
tetraspanins [24, 25]. Of the integrins that relate the podocyte
to the GBM, 𝛼3𝛽1 integrins are the most numerous [16].
The highly specialized structure of the podocyte is essential
for its ability to function as part of the glomerular filtering
unit, and when its structural integrity is compromised, so
is its ability to parse out what material from the blood
may pass through to form the ultrafiltrate. Much of the
structure of the podocyte is based on its actin cytoskeleton,
whose numerous interactions with surface proteins such as
podocalyxin and nephrin highlight the fact that though the
surfaces of the foot processes may seem to have separate
roles and constitutional make-up, they are in fact highly
related. Figure 1 illustrates the basic cellular organization of
the podocyte foot process, with specific emphasis upon the
localization and the protein-protein associations amongst the
soon to be discussed biomarkers of podocytopathy.
Podocytes are responsible for maintaining normal glom-
erular filtration in a number of ways: both in mechanical and
functional fashions. Via the slit diaphragm, the podocytes
(as previously described) act as barrier to protein based
upon size. By way of the negatively charged surface of the
podocyte foot processes, they serve as a barrier based on
charge thus impairing passage of anionic proteins/material
[12]. As a pericyte-like cell that encircles glomerular capillar-
ies, a podocyte physically influences its vascular neighbors.
Podocytes act as both a maintainer of glomerular capillary
lumen patency and as a counteracting support against the
intracapillary hydrostatic pressure (approximately 60mmHg,
a pressure that is greater than that found in most capillary
networks) that would otherwise cause bulging [26]. It is
notable in the pathogenesis of glomerulosclerosis that when
podocytes are lost due to injury, the intracapillary pressure
is no longer held in check by the podocyte counter-pressure,
allowing the nude glomerular capillary to bulge and abut the
parietal epithelium [10, 22]. Adhesions between the glomeru-
lar capillary and parietal epithelium are histologically evident
in states when podocyte loss occurs [4]. In a functional
manner, podocytes also lend to normal glomerular integrity
by way of the elaboration of vascular endothelial growth
factor-A (VEGF-A), which is necessary for the maintenance
of the glomerular endothelium.VEGF-Ahas been considered
to play a role in the pathogenesis of preeclampsia, with
reduced expression of VEGF-A resulting in proteinuria and
endotheliosis: both are pathognomonic renal findings in
preeclampsia. The connection between preeclampsia and
podocytes has been enlightened by findings that podocytes
can be found in urine of women with preeclampsia and may
be a diagnostic tool in diagnosing this gestational pathology
[27]. Further glomerular capillary maintenance by podocytes
is evident by their expression of angiopoietins (specifically
Ang1) and the presence of Ang1 receptors (protein tyrosine
kinase 2-Tie2) on glomerular capillary endothelium [28, 29].
The relationship between the podocyte and the underlying
GBM is more than a static physical relationship. It has been
shown that while both the glomerular endothelium and
podocyte are responsible for production of the GBM in the
developing kidney, there is a transition where podocytes
resume responsibility and continue to add material to the
GBM even at the stage of the adult glomerulus [30]. In addi-
tion, podocytes clear material that may deposit in the GBM,
aiding in our understanding of how this filtering apparatus
remains unclogged from debris over time [31]. Podocytes
have also been shown to produce platelet-derived growth
factor (PDGF), which has trophic properties for neighboring
mesangial cells [32]. There is also evidence that podocytes
may have a hand in immune response, with localization and
isolation of CD80 and complement receptor 1 (CR1) from
podocytes [33, 34]. The podocyte plays not simply a static,
mechanical role, but it also has paracrine activity through
elaboration of factors necessary for maintaining glomerular
homeostasis andmay have an active role in immunemediated
functions within the glomerulus.
There are numerous etiologies for which podocyte injury
manifests as clinically evident disease: most notably as
proteinuria. When injured, podocytes undergo histologically
notable changes in structure that directly relate to a reduc-
tion of normal filtrating function. Most characteristically,
podocytes can undergo a process termed effacement, where
the normal cellular architecture of the foot process is altered
and results in flattening and spreading of the foot process
along the GBM and disruption of the slit diaphragm. Efface-
ment can manifest whenever the following occurs: when the
slit diaphragm and its related protein-protein interactions
are disrupted, when there is interference in the normal
association of the foot processes with the underlying GBM,
when there is reorganization of the actin cytoskeleton and
its related protein-protein interactions, or when there is
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Figure 1: The protein biomarkers discussed in the paper are highlighted in this figure to show their cellular localization and the protein-
protein associations that occur in glomerular podocyte foot processes. The podocyte is situated upon the glomerular basement membrane
(GBM) and is anchored to it in part by alpha 3 integrins (Int𝛼3). The slit diaphragm is illustrated with nephrin from adjacent foot processes
interacting and forming a “zipper-like” structure. One can appreciate how the actin cytoskeleton (composed of F-actin) brings together the
apical, lateral, and basal surfaces of the foot process: membrane proteins (podocalyxin, nephrin, alpha 3 integrin, etc.) via adaptor proteins
(CD2AP, 𝛼-actinin 4, etc.) interact with actin, and as such they can modulate it. Wilms tumor protein 1 (WT1) has been identified as a
transcription factor and is also localized within exosomes. Mindin has been localized within glomeruli, specifically to podocytes, and in cell
culture found to be secreted into culture medium. Further details of each protein can be found in their respective sections within the paper.
disruption of the normal negatively charged apical surface
of the foot processes [14]. Effacement can be accompanied
by progressive changes in podocyte structure characterized
by vacuolization, formation of pseudocysts, apical membrane
microvillus formation, disruption of podocyte foot processes
from the underlying GBM, and consequentially, in appropri-
ate conditions, loss of podocytes [8, 35]. Figure 2 depicts a
simplified view of the glomerular filtration apparatus and the
consequences of podocyte injury.
Glomerular pathology that includes injury to podocytes
has been classically diagnosed by the analysis of biomarkers
related to renal dysfunction and structural damage: blood
urea nitrogen (BUN), creatinine in urine and blood, measure
of creatinine clearance, and qualitative/quantitativemeasures
of proteinuria. Though these measures are generally cheap
and noninvasive, the final diagnosis of any patient with
a suspected glomerulopathy is based upon the histologic
findings from a kidney biopsy: a procedure that is not without
risk [36]. The integrity of the slit diaphragm—a zipper-like
interaction ofmembrane proteins between adjacent podocyte
foot processes—is necessary for the inhibition of abnormal
passage of proteins which have the size of and larger than
albumin into the ultrafiltrate, and once the slit diaphragm
is disrupted by way of podocyte injury, one can note the
states of proteinuria that can range from inconspicuous to
that of a florid nephrotic state (>3 g/day protein in urine).
It should be added that while proteinuria is commonly
associated with podocyte/slit diaphragm disruption, injury
to the GBM or the glomerular capillary endothelium also
results in proteinuria and thus brings to attention the lack
of specificity of proteinuria for podocyte damage [37]. The
level of proteinuria has also been found to be limited as a
measure of monitoring disease progression as well as being
limited for themonitoring of disease response to therapy [38].
Quantification of proteinuria is, however, still recognized as
a simple and useful measure of glomerular injury and has
been shown to correlate with progression of chronic kidney
disease and as an indicator for increased cardiovascular
morbidity/mortality [39]. To be curt, this paper is not aiming
to dispel the proven worth of utilizing proteinuria as an indi-
cator of glomerular/podocyte injury, but instead it aims to
highlight the advantages—or weaknesses—of novel markers
of podocytopathy and the potential they hold for clinical
utility. While the strengths, weaknesses, and proper usage
of measuring protein in the urine for diagnostic purposes
has been discussed in many papers [40–43], as with any
instrument inmedicine, there comes a timewhen better tools
come to be and advance the ability of the clinician to more
confidently care for a patient. The fact that proteinuria can
be measured noninvasively and relatively cheap with a urine
dipstick argues for the continuing usage of it as a biomarker of
glomerular injury, at least until more advantageous tools fall
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Figure 2: A simplified glomerulus and initial segment of the nephron are depicted; mesangia and the interweaved, capillary tuft structure
are not shown to focus upon a single capillary and its related glomerular filtration apparatus. Also not depicted is the continuity between the
visceral and parietal epithelial layers of the glomerulus. A glomerular capillary is lined by the fenestrated endothelia, which is intimately
associated with the glomerular basement membrane (GBM). Also associated with the GBM is the visceral epithelial layer consisting of
podocytes; the podocyte is made up of a cell body and processes that allow it to wrap finger-like projects about glomerular capillaries.
Interposed between podocyte foot processes is a space spanned by the slit diaphragm—a key structure in the limitation of particles (based
on size) from passing into the ultrafiltrate. Material/fluid that passes through the endothelia, GBM, and podocyte/slit diaphragm (these three
constitute the glomerular filtration apparatus) makes it into Bowman’s space, and the fluid at this point is termed ultrafiltrate.The ultrafiltrate
from here passes through the length of the nephron—withmodification possible—and urinary tract.The podocytes that lay on the left side of
the shown capillary (1) are shown in a normal, healthy state: foot processes exist with developed slit diaphragms in between. In contrast, the
right side of the capillary exhibits podocytes of an injured phenotype (2) effacement is present (other manifestations of an injured podocyte
are not depicted, but can be read about in the paper), and at times podocytes may shed material later to be found in urine. If the podocyte is
injured to a certain degree, it may detach from the underlying GBM and be observed in collected urine. A GBM denuded of podocytes may
develop and lend itself as a surface for adherence with the parietal epithelium.
into hand. With that, we shall proceed with the discussion
of some potentially more efficacious indicators of podocyte
injury.
Over the last two decades, investigations have shed light
on the fact that podocytes are present in the urine in
concurrence with a renal disease state and that podocy-
turia and biomarkers specific for podocytes themselves can
relate to disease progression. Figure 1 depicts a simplified
view of the glomerular filtration apparatus and conse-
quences of podocyte injury. It has also been noted that
the level of podocyturia is a more sensitive indicator of
disease activity than the level of proteinuria [44]. Notice
should be taken of the fact that culture-viable podocytes
can be isolated from the urine of healthy volunteers, so
the specificity of podocyturia for glomerulopathies is not
perfect [45]. In the urine of patients with certain glomeru-
lopathies, evidence of podocyte injury can be found with
the presence of viable podocytes (capable for the usage in
primary cell culture), apoptotic podocytes, and podocyte
derived exosomes and granular structures—all which have
the possibility of being utilized as potential biomarkers of
podocyte injury [46]. Urinary biomarkers that have been
found to be specific for podocyte injury include proteins
(podocalyxin, nephrin, podocin, CR1, CD80, synaptopodin,
GLEPP-1, mindin, alpha 3 integrin, CD59, and Wilms tumor
protein 1-WT1), podocyte specific messenger ribonucleic
acid (mRNA) (nephrin, podocin, synaptopodin, podoca-
lyxin, CD2-associated protein-CD2AP, ACTN4-encodes for
𝛼-actinin 4, PTPRO-encodes for GLEPP-1, WT1, and B7-1-
encodes for CD80), an exosomal transcription factor (WT1),
and podocalyxin positive granular structures (PPGS). Uti-
lizing immunofluorescent staining, Western blot, enzyme-
linked immunosorbent assay (ELISA), flow cytometry, and
mass spectrometry, protein-based biomarkers are elucidated
fromurine samples of patients with glomerular disease, while
polymerase chain reaction (PCR) is utilized to quantify the
presence of podocyte specific mRNA. Figure 3 illustrates the
premise of the following urinary biomarkers in podocy-
topathies.
This review will describe the urinary biomarkers of
podocyte injury that have been investigated to date: proteins,
podocyte specific mRNA, an exosomal transcription factor,
and PPGS. A brief characterization of each biomarker in
normal and injured podocyte states shall be discussed along
with an overview of how each has been examined as a urinary
biomarker of podocyte injury.
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Figure 3: Podocytes envelop the capillary tuft of the glomerular body and are an integral part of the glomerular filtration apparatus. If
podocytes are injured or lost via any number of mechanisms, podocyte specific material or whole podocytes themselves may traverse the
length of the nephron and urinary tract to be collected/observed in the excreted urine product.With suchmaterial in hand, a number of noted
techniques can be used to identify the podocyte derivations. More poignantly, investigations to date have described that such techniques can
identify podocyte specific proteins, mRNA, an exosomal transcription factor, and podocalyxin positive granular structures.
2. Podocalyxin
Podocalyxin is an anionic, transmembrane protein that
localizes to the apical membrane of glomerular podocytes.
Aside from the kidney, podocalyxin is also localized in
hematopoietic progenitor cells, vascular endothelium, and
certain neurons [47–49]. Structurally, podocalyxin’s extracel-
lular portion consists of O-glycosylated, sialylated (providing
the anionic charge), and N-glycosylated domains, along with
a globular domain and a juxtamembrane stalk [50]. Intra-
cellularly, podocalyxin has putative sites for phosphorylation
alongwith a PDZ-binding domain. It is this PDZ domain that
allows for podocalyxin’s interaction with Na+/H+ exchanger
regulatory factors 1 and 2 (NHERF1 and NHERF2) [51, 52].
Podocalyxin also interacts with ezrin—a protein that is found
to be complex with NHERF2 and that binds actin—and thus
relates podocalyxin to the cytoskeletal network that dictates
podocyte structure [53]. Podocalyxin is also important in
normal development of glomeruli, for knockout mice that do
not express podocalyxin, and normal podocyte architecture
is disrupted with histologic evidence of absence of foot
processes and slit diaphragms [54]. It seems that in the
glomerular podocyte, podocalyxin plays a role as the main
contributor to the anionic surface of foot processes, and via
its relation with the actin cytoskeleton it is involved in the
normal formation and maintenance of podocyte structure.
Hara et al. first noted that podocalyxin in urine was
related directly to podocyte injury in patients with IgA
nephropathy and Henoch-Scho¨nlein purpura nephritis [55,
56]. Many papers thereafter used their technique of immuno-
staining against podocalyxin in urine samples to detect
podocyte material. Hara had also noted that when podoca-
lyxin was tested as a urinary biomarker for detecting the
presence of varying glomerular diseases, it had a sensitivity
of 88.4% and specificity of 100% [57]. When urine from
patients with diabetes mellitus was examined, subjects with
more severe disease (determined by severity of albuminuria)
had significantly more podocalyxin positive podocytes in
the urine than diabetic patients with less severe disease
(defined as microalbuminuria equaling 20–200𝜇g/min urine
albumin excreted) and compared to healthy controls [58].
The same study also showed that treatment with trandolapril
(an angiotensin converting enzyme inhibitor) reduced albu-
minuria and podocalyxin positive podocyturia in diabetic
patients: a proof that podocalyxin and podocyturia are
biomarkers that can be used to monitor therapeutic efficacy
and disease progression. To further substantiate urinary
podocalyxin’s ability to reflect change in disease status with
therapy, the adriamycin rat model of nephropathy induced
increases proteinuria, podocyturia (detected via podocalyxin
immunofluorescent staining), and foot process width. Treat-
ment with 1,25-dihydroxyvitamin D
3
reduced all mentioned
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parameters, showing that efficacy of therapy could be fol-
lowed with the monitoring of urinary podocalyxin [59]. An
investigation of adult patients with IgA nephropathy revealed
that the severity of acute extracapillary abnormalities corre-
lated with the level of urinary podocalyxin and that some
patientswith lower proteinuria and high urinary podocalyxin
had poorer prognoses.The latter finding exhibits that in some
cases proteinuria does not necessarily reflect the severity
of disease but that the urinary level of podocalyxin does
[60]. When podocytes, casts, and granules from the urine of
children diagnosedwith IgA nephropathywere immunofluo-
rescently stained for podocalyxin, the degree of fluorescence
directly correlated with the degree of glomerular epithelial
injury as noted through renal biopsy histologic examination
of the same patients [61]. These results would tend to allow
one to believe that in children—and possibly adults—with
IgA nephropathy, the degree of glomerular involvement and
injury could be anticipated before renal biopsy through
quantification of podocalyxin positive urine material, as well
as a possible biomarker to follow disease progression. In
a study examining patients diagnosed with focal segmental
glomerular sclerosis (FSGS), it was shown that patients that
were significant excreters of podocalyxin positive cells in the
urine had a fall of serum creatinine in follow-up, lending
to recovery [62]. Podocalyxin has been utilized as a urinary
biomarker in studies examining podocyturia in preeclamptic
women [63].When podocalyxin was comparedwith podocin
and nephrin in women with preeclampsia, it was found that
podocin had superior diagnostic accuracy [64]. A separate
study showed that levels of urinary podocalyxin were sig-
nificantly greater in women with preeclampsia than normal
pregnant women [65]. So where podocalyxin lies in the panel
of podocyte biomarkers in the diagnosis of preeclampsia is yet
to be decided. Urinary podocalyxin has also been detected—
utilizing ELISA—in the urine of patients with acute kidney
injury, and it was notable that urinary podocalyxin levels
were greatest, whilst creatinine levels were recovering [66].
This group utilized the same assay to detect urinary podoca-
lyxin in diabetic patients with glomerulopathy and found
that there was a significant difference in control, healthy
subjects and normoalbuminuric, diabetic patients [67]. This
illustrates how a urinary biomarker specific for podocytes
can detect disease otherwise passed over by the conventional
monitoring of albuminuria. Early detection of podocyte
lesions in diabetic glomerulopathy could give the clinician
a chance to revert kidney disease by way of implementing
appropriate therapeutic measures—a chance missed if one
relied solely on the level of albuminuria. In order to create
a more objective measure of urinary podocalyxin, a recent
investigation used flow cytometry to detect the biomarker in
the presence of glomerular disease [68].
Urinary podocalyxin mRNA expression has been illus-
trated to be significantly greater in patients with diabetic
nephropathy compared to healthy controls, the level of
mRNA increased with progression of disease, and the level
of urinary podocalyxin mRNA positively correlated with
urinary albumin excretion, BUN, and with serum creatinine
[69]. Results from the same investigation showed that urinary
podocalyxin mRNA negatively correlated with estimated
glomerular filtration rate (eGFR). It should be noted that
the quantitative analysis of urinary podocalyxin mRNA—
and not just qualitative—should be recommended for clinical
analysis, for podocalyxin mRNA has been shown to be
expressed in urine of healthy, human volunteers [45]. All
in all, it can be seen from the summary of studies utilizing
podocalyxin as a urinary biomarker of podocyte injury—
incurred through numerous different pathologies—that there
is potential for its usage in the clinical setting to guide
diagnosis and follow disease progression.
3. Nephrin
Nephrin is a 180 kDa transmembrane protein localized on the
lateral surface of the podocyte foot process and is a major
component of the slit diaphragm. Aside from podocytes,
nephrin can be found in central nervous system tissue
and pancreas, specifically in the 𝛽-cells of the islets of the
Langerhans [70]. In the capillary loop stage of nephron devel-
opment, nephrin can be localized at junctures of incipient
podocyte foot processes, while nephrin mRNA expression
can be detected in the S-shaped bodies of the developing
nephron [71]. Nephrin—the product of the NPHS1 gene—
was discovered when mutations in NPHS1 were found in
patients with congenital nephrotic syndrome of the Finnish
type [72]. Examination of kidney samples from patients with
congenital nephrotic syndrome of the Finnish type shows
thinning of the lamina densa layer of the GBM, yet otherwise
insignificantly different from healthy, control kidneys [73].
An experiment utilizing a murine model, in which the Nphs1
gene is inactivated, presents histologic evidence of podocyte
foot process effacement and absence of a slit diaphragm,
along with proteinuria and the immediate death soon after
parturition [70]. Nephrin associates and colocalizes with
podocin and the actin cytoskeleton, and the interaction of
nephrin with the actin cytoskeleton is done so through
an association with CD2AP [74, 75]. In addition, nephrin
forms complexes—as proven through coimmunoprecipita-
tion and pull-down assays—with cadherins, p120 catenin,
and scaffolding proteins zonula occludens protein 1 (ZO-1),
CD2AP, and calcium/calmodulin-dependent serine protein
kinase (CASK) [76]. There is also a proof that nephrin and
the slit diaphragm can be a source of intracellular signaling
mechanisms in podocytes. This was made evident by the
fact that nephrin expression triggers cellular activation via
protein kinase p38 and the c-Jun N-terminal kinase in
HEK293T cells [23]. Cellular activation was enhanced in the
presence of podocin, and this would suggest that signaling
involving the slit diaphragm requires normal interaction of
nephrin and podocin. Nephrin’s interaction with the actin
cytoskeleton via CD2AP might also lend to the idea that
nephrin’s role in intracellular signaling may be transmissible
to the cytoskeleton and result in structural changes. It can be
appreciated that nephrin has a significant role as a constituent
of the slit diaphragm, a role in maintaining normal podocyte
foot process architecture, and an additional position in intra-
podocyte signaling.
Urinary nephrin protein and mRNA have also been
examined in patients with a number of glomerulopathies and
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hold potential as clinically useful biomarkers of podocyte
injury. A study of patients with type 1 diabetes noted that
while microalbuminuria was used for the early detection of
kidney involvement in disease, advanced glomerulopathywas
already present and presented that 30%of normoalbuminuric
patients had nephrinuria; all healthy controls in the study
were found to be negative for urinary nephrin [77]. The
detection of urinary nephrin from type 2 diabetic patients
determined to be normoalbuminuric also showed that uri-
nary nephrin was a more sensitive marker of nephropathy in
diabetes than the measure of urinary albumin [78]. Relatedly,
observation of the FVB/NJ Akita mouse model of diabetic
nephropathy noted that urinary nephrin could be detected
before detectable albuminuria develops [79].These data again
highlight how a urinary biomarker specific for podocytes
can detect disease otherwise passed over by the conven-
tional monitoring of albuminuria. Investigators have recently
shown that preeclamptic women had significantly higher lev-
els of urinary nephrin than healthy pregnant women [65] and
that there was a correlation between urinary nephrin levels
and urinary protein, serum creatinine, and diastolic blood
pressure in preeclamptic women [80]. Utilizing Heymann
nephritis model, immunohistochemistry and PCR showed
a decrease in both urinary nephrin protein and mRNA
expression compared to healthy controls, and this decrease
was noted before the onset of proteinuria was detected [81].
As part of the same study, it was shown that urinary nephrin
could be quantified byWestern blot and that healthy animals
did not excrete detectable nephrin in their urine.
A second study utilizing a passive Heymann nephritis
model found that nephrin protein and mRNA could be
quantified from cells isolated from collected urine samples
[46]. In a study using a streptozotocin model, it was noted
that urinary cells could be stained against nephrin and that,
in healthy controls, cells could not be detected in urine
[82]. The same investigation showed that the cells collected
from streptozotocin-treated rats were viable for primary
culture. Aaltonen et al. noted similarly that urinary nephrin
could be detected early in the streptozotocin rat model
[83]. Podocyturia determined via nephrin staining did not
significantly predict preeclampsia; however, the study noted
that the urine of somewomenwith severe diseasewas positive
for podocyturia by nephrin staining [84]. Urinary nephrin
mRNA levels increased after instigation of glomerular injury
in models utilizing human diphtheria toxin receptor (hDTR)
transgenic rats (expressing hDTR specifically on podocytes);
however, on follow-up urine analysis, nephrin mRNA could
not be detected [85]. Another study using hDTR transgenic
rats showed that the podocin : nephrin mRNA ratio corre-
lated with the renal histologic state [86]. The same study
showed that human patients diagnosed with systemic lupus
erythematosus (SLE) with associated glomerular disease
had measurable levels of urinary nephrin mRNA. Urinary
nephrin mRNA expression significantly correlated with the
degree of proteinuria in patients with diabetic nephropathy,
showing that nephrin mRNA in the urine could possibly
be clinically used as a biomarker to follow glomerulopathy
progression in diabetic patients [87]. In patients with lupus
nephritis, urinary nephrin mRNA could be measured and
was found to correlate with the level of proteinuria [88].
Urinary nephrin mRNA was found to correlate with the
decline of renal function and degree of proteinuria in a
study examining the progression of disease in a group of
patients with diagnoses of diabetic glomerulosclerosis, IgA
nephropathy, minimal change disease, and membranous
nephropathy [89]. Further, supporting the strength of urinary
nephrin mRNA in clinical utility, the level of mRNA was
significantly greater in the urine of patients with glomerular
kidney disease than healthy controls, and the level of urinary
nephrin mRNA could differentiate between proliferative and
nonproliferative disease [90]. Urinary nephrin mRNA levels
could differentiate between preeclamptic women and healthy
controls, as well as being used to differentiate between
preeclamptic women and women with gestational diabetes
[91]. Quantitative analysis of urinary nephrin mRNA—and
not just qualitative—should be recommended for clinical
analysis, since nephrin mRNA was expressed in urine of
healthy, human volunteers [45]. It can be seen that the
evidence for urinary nephrin (protein and mRNA) being
used as a biomarker of podocyte injury is building, and in
a number of different glomerulopathies could be of clinical
use.
4. Podocin
Podocin is a 42 kDa membrane-associated protein that has
a hairpin structure resulting with both N- and C-terminal
ends located in the cytoplasm.TheNPHS2 gene—the product
being podocin—is mutated in certain patients with auto-
somal recessive steroid resistant nephrotic syndrome, with
disease manifesting early in childhood and progression to
end-stage renal failure [92]. In development, podocin mRNA
is first expressed in the S-shaped body of the incipient
nephron, while podocin protein is first expressed in the
capillary loop stage. In the mature kidney, podocin mRNA
expression is only detectable in podocytes [93]. Localized
to the lateral membrane of the podocyte foot process at the
insertion of the slit diaphragm, podocin can be found in an
oligomeric formation within lipid rafts and interacts with
nephrin and CD2AP by way of a COOH-terminal domain
[75]. Podocin plays an integral role in nephrin mediated
cellular signaling, and thus it has a putative role in podocyte
structure and function [23].
In a number of studies to date, podocin protein and
mRNA have been shown to be quantifiable in the urine of
both animal models of glomerulopathies and humans with
renal disease. In a concerted effort to objectively measure a
urinary podocyte biomarker, a recent study used mass spec-
trometry to detect podocin in urine samples of preeclamptic
women [94]. It would be highly interesting to follow up with
further studies detecting other discussed podocyte biomark-
ers with mass spectrometry. Nakatsue and colleagues have
shown that while urinary nephrin was detectable by Western
blot in diseased Heymann nephritis animals, podocin could
not be detected in the urine of the same animals [81].
However, a different study from a second group had shown
that podocin protein and mRNA could in fact be quantified
from cells isolated from collected urine samples in passive
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Heymann nephritic rats [46]. Whether podocin protein can
be quantified from urine of Heymann nephritis animals or
the human equivalent of membranous nephropathy is still to
be determined. As previously described in the podocalyxin
section, in women, podocin had greater diagnostic accuracy
compared to the utilization of podocalyxin and nephrin
as biomarkers of podocytes in urine for determining the
presence of preeclampsia [64]. A separate study noted sim-
ilarly that urinary derived podocin mRNA was significantly
elevated from preeclamptic women compared to healthy
controls [91]. In a study using a streptozotocin model, it was
noted that urinary cells could be stained against podocin
and that in healthy controls cells couldnot be detected in
urine [82]. Urinary podocin mRNA levels increased after the
instigation of glomerular injury in models utilizing hDTR
transgenic rats, and on follow-up urine analysis podocin
mRNAcould still be detected—in contrast to urinary nephrin
mRNAwhich could not be detected [85]. Data from the same
study showed that urinary podocin mRNA levels were found
to positively correlate to the level of proteinuria, and human
patients diagnosed with SLE with associated glomerular
disease had measurable levels of urinary podocin mRNA.
An investigation using hDTR transgenic rats illustrated that
the podocin : nephrin mRNA ratio correlated with the renal
pathohistologic state [86]. In patients with lupus nephritis,
urinary podocin mRNA could be measured, and as the
patients are followed over time, urinary podocin mRNA
decreased along with a worsening glomerular filtration rate
(GFR) [88].This may be the evidence to support that urinary
podocin mRNA could be a clinically useful biomarker for
following disease progression in patients with lupus nephritis
since it seems to trend along with the GFR, a measure of
glomerular function.Urinary podocinmRNAexpressionwas
significantly greater in patients with diabetic nephropathy
compared to healthy controls, the level of mRNA increased
with progression of disease, and the level of urinary podocin
mRNA positively correlated with levels of urinary albumin
excretion, BUN, and with serum creatinine [69]. Urinary
podocin mRNA could also be collected from some dogs
with chronic kidney disease, but this study did not contain
a healthy control group, so the significance of these findings
is yet to be determined [95]. Urinary podocin mRNA was
found to correlate with the decline of renal function in a
study that examined the progression of disease in a group
of patients with diagnoses of diabetic glomerulosclerosis,
IgA nephropathy, minimal change disease, and membranous
nephropathy [89]. Thus it can be seen that urinary podocin
protein and mRNA have been found to be viable biomarkers
of podocyte injury, though further investigations will be
necessary to see their efficacy as a clinical tools.
5. Complement Receptor 1 (CR1)
Complement receptor 1 (CR1)—also known as CD35 or
C3bR—is a 200 kDa membrane bound receptor that within
the adult glomerulus is expressed only in podocytes [96,
97]. Outside of the glomerulus, CR1 expression is found
in follicular dendritic cells, the Langerhans cells in the
skin, the Ku¨pffer cells, circulating erythrocytes, neutrophils,
monocytes, and T-lymphocytes [98, 99]. CR1 protein is
expressed in both fetal podocytes of the developing kidney
and in the mature, adult kidney. In the fetal kidney, CR1
mRNA is detectable in immature podocytes in early stages of
glomerular differentiation, specifically after vascularization
of the developing glomerulus [33, 100]. By binding C3b—the
active form of C3—CR1 regulates complement activation on
the cellmembrane by inhibiting activation of the complement
pathway [101]. The specific role that CR1 plays on the surface
of podocytes has yet to be fully elucidated, but one may
assume that it may hold a protective role for podocytes from
immune attack.
CR1 positive vesicles have been found by Western blot in
the urine of healthy patients, and in comparison, urinary CR1
expression was decreased in patients with more advanced
cases of SLE [102]. In a study by Hara, the diagnostic
sensitivity and specificity of urinary CR1 for patients with an
amalgam of glomerulopathies were determined to be 51.4%
and 100%, respectively [57]. CR1 was also noted to have
been localized to PPGS found in the urine of patients with
active glomerulonephritis and nephrotic syndrome [103]. It
has been shown that CR1 can be found in the urine of both
healthy subjects and patients afflicted by glomerulopathies,
but more work must be done in order to understand the
expression of urinary CR1 in individual glomerular disease
states. With the evidence in hand, it appears that CR1’s utility
in monitoring podocyte injury is lacking.
6. CD80
CD80 (also referred to as B7-1) is a 53 kDa membrane-
associated protein that in the glomerulus is localized exclu-
sively in podocytes, but it can also be found in renal tubules
[104, 105]. It is better known for its role in the immune
system as a costimulatory receptor involved in T-lymphocyte
activation [104]. CD80 activation by puromycin in cultured
podocytes is found to attenuate expression of nephrin and
results in foot process effacement and retraction, providing
insight on how CD80 can influence podocyte structure and
function [106]. The ability of CD80 to regulate podocytes’
filtering capacity is also shown when lipopolysaccharide is
injected in mice, resulting in increased CD80 expression
and proteinuria, and in mice that are knockouts for CD80,
proteinuria does not occur [105]. Therefore, the immune
stimulatory role of CD80within the glomerularmilieu would
support the idea that it may modulate immune mediated
injury to podocytes.
CD80 and its mRNA (B7-1) can be detected and mea-
sured in collected urine and may be potential biomarkers
of podocyte injury. Urinary levels of CD80 in patients
with relapsed minimal change disease were significantly
greater when compared to those in patients with minimal
change disease in remission, SLE (with and without protein-
uria), other glomerulopathies (FSGS, membranoprolifera-
tive glomerulonephritis, IgA nephropathy, and membranous
nephropathy), and healthy control patients [104]. Data from
a second study by the same group showed that urinary CD80
was increased in patients with minimal change disease in
relapse compared to patients with minimal change disease
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in remission or those with FSGS [34]. These results support
that urinary CD80 could be used clinically to differentiate
between patients with the relapsed minimal change disease
and FSGS. Additionally, the level of urinary B7-1mRNA was
found to be enhanced in patients with glomerular kidney
disease compared to that of healthy subjects [90]. Promising
data is presented for the utility of urinary CD80 for a
biomarker of podocytopathy; however, much more work is
needed to substantiate confidence in its clinical usage, and the
fact that CD80 can also be derived from tubular epithelium
reduces confidence in its specificity.
7. Synaptopodin
Synaptopodin (also referred to as podocyte protein 44-pp44)
is an actin binding protein, and through this interaction it can
modulate the podocyte actin cytoskeleton and resultant cellu-
lar function [107]. Synaptopodin is immunohistochemically
expressed in podocyte foot processes and colocalizes with
actin within the cytoplasm, and in the central nervous system
synaptopodin mRNA expression is positive in the olfactory
bulb, cerebral cortex, striatum, and hippocampus [108].
Synaptic plasticity in the hippocampus seems to be reliant on
the activity of synaptopodin and its interaction with calcium
stores [109]. During renal development, synaptopodin is first
identified in the incipient glomerulus during the capillary
loop stage—the stage at which foot processes formulate
[110]. Synaptopodin—in the fully developed glomerulus—
is exclusively expressed in podocytes [111]. More specifi-
cally, synaptopodin is a marker of the well-differentiated
podocytes, as an investigation into the culturing of podocytes
noted that synaptopodin expression is synonymous with the
development of foot processes and a phenotype similar to
that found in vivo [108]. It has been shown that synap-
topodin is proteolytically downregulated by cathepsin L—
a protease that is induced in the diseased state—resulting
in actin reorganization, podocyte architecture change, and
proteinuria [107, 112]. Thus the role that synaptopodin plays
in maintaining the actin cytoskeleton is evident when its
activity is attenuated, with subsequent podocyte dysfunction.
There are a number of studies that have examined the
presence and utility of urinary synaptopodin protein and
mRNA to determine podocyte damage. It was found in
diabetic nephropathy patients that urinary synaptopodin
mRNA significantly correlated with glomerular podocyte
number observed in histologic examination, showing that
urinary synaptopodin mRNA may be clinically applicative
in monitoring disease progression in these patients [113].
Data from another study examining patients with diagnosed
diabetic nephropathy presented that urinary synaptopodin
mRNA correlated with the degree of proteinuria [87]. In
patients with lupus nephritis, urinary synaptopodin mRNA
was measured, and as the patients were followed over
time, urinary synaptopodin mRNA decreased along with
the GFR [88]. This may be the evidence to support that
urinary synaptopodin mRNA could be a clinically useful
biomarker for following disease progression in patients with
lupus nephritis since it seems to trend along with the GFR.
Urinary synaptopodin mRNA expression was significantly
greater in patients with diabetic nephropathy compared to
healthy controls, the level of mRNA increased with pro-
gression of disease, and the level of urinary synaptopodin
mRNApositively correlated with the level of urinary albumin
excretion and BUN [69]. Using a streptozotocin model of
diabetic nephropathy, urinary cells could be stained against
synaptopodin; however, in healthy controls, urinary cells
stained for synaptopodin could not be detected [82]. The
same group has also shown that synaptopodin protein and
mRNA could be quantified from cells isolated from urine
samples of passive Heymann nephritic rats [46]. Urinary
synaptopodin mRNA was found not to correlate with the
decline of renal function in a study examining the progression
of disease in a group of patients with diagnoses of dia-
betic glomerulosclerosis, IgA nephropathy, minimal change
disease, and membranous nephropathy [89]. In addition,
synaptopodin mRNA was found in urinary podocytes of
both FSGS patients and healthy humans [45]. Data from
a study that included patients with a number of different
glomerulopathies showed that urine sediment did not stain
for synaptopodin [57]. Urinary synaptopodin is also noted to
be a poor indicator of the preeclamptic state, as it was found
to have diagnostic sensitivity of only 38% and specificity of
70% [114]. It is difficult to conclude from the collected studies
if urinary synaptopodin protein or mRNA can be utilized
regularly with confidence in clinical practice as biomarkers
of podocyte injury.
8. Glomerular Epithelial Protein 1 (GLEPP-1)
GLEPP-1 (also referred to as protein tyrosine phosphatase
receptor type-O—PTPRO) is an apical-membrane-
associated protein tyrosine phosphatase found on glomerular
podocytes [115, 116]. Central nervous system expression of
Ptpro (encodes for GLEPP-1 protein) is localized to the
olfactory bulb, developing neocortex, thalamus, and
hippocampus [117]. In the developing kidney, GLEPP-1
protein expression is first detected during the S-shaped
stage of the glomerular anlage, with increasing expression
noted in podocytes through development and into maturity
[118]. GLEPP-1
󸀠
s importance in the maintenance of normal
glomerular filtration has been shown in patients diagnosed
with idiopathic nephrotic syndrome, steroid resistant
subtype, that different mutations in PTPRO are to blame
in resultant phenotypic changes of podocytes and massive
proteinuria [119]. In Ptpro knockout mice, altered podocyte
architecture can be observed with foot processes shorter
and broader, and functionally these mice have reduced
glomerular filtration function (25–50% lower GFR than
wild-type) and a propensity for hypertension if the kidney
is placed under increased functional stress (as exhibited in
the animal model after nephrectomy) [21]. GLEPP-1 has an
important role to play in normal podocyte function and
the maintenance of glomerular integrity, and its activity as
a phosphatase lends to the hypothesis for a putative role in
intracellular signaling.
Urinary GLEPP-1 protein and Ptpro mRNA have been
examined for usage as biomarkers of podocyte injury.
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Using a streptozotocin model of diabetic nephropathy, uri-
nary cells could be stained against GLEPP-1; however, in
healthy controls, urinary cells stained for GLEPP-1 could
not be observed [82]. The same group also presented that
GLEPP-1 protein and Ptpro mRNA could be quantified
from cells isolated from urine samples of passive Heymann
nephritic rats [46]. Utilizing a puromycin aminonucleoside
(PAN) nephrosis model, Ptpro mRNA was found in the
urine of rats after insult, but not in untreated, healthy rats
[120]. It is obvious that there is a paucity of data relating to
GLEPP-1’s usage as a urinary biomarker of podocytopathy,
and evaluation of its efficacy clinically is not possible at this
time as thus.
9. Mindin
Mindin (also known as spondin-2) is a secreted protein that
becomes a constituent of extracellular matrix, as it was first
observed in the zebrafish floor plate [121]. Mindin mRNA is
found in the brain, liver, spleen, placenta, lung, heart, kidney,
muscle, and thymus, and in the central nervous system
mindin has been implicated as a promoter of hippocampal
neuron development [121, 122]. In the kidney, the immuno-
histochemistry shows that mindin localizes predominately
to podocytes within the glomerulus and that secretion of
mindin is appreciated in podocyte cell culture [123]. Inflam-
matory reactions are also mediated by mindin, and this has
been illustrated inmindin knockout mice that are resistant to
lipopolysaccharide-induced septic shock, and the same mice
are not as capable in clearing bacterial infections in vivo [124].
Mindin is found to bind neutrophils through the involvement
of integrins, and with localization in the glomerulus mindin
may have a role as a recruiter of inflammatory cells in the
pathogenesis of glomerular lesions [125].
While mindin has not previously been utilized as a
biomarker of podocyte injury, a recent study byMurakoshi et
al. has shed light uponmindin’s histologic andurinary expres-
sion in diabetic nephropathy [123]. The study presented that
mice fed on high calorie diets expressed augmented levels of
glomerular mindin protein and mRNA than mice fed on a
standard diet. As well, mice fed on high calorie diets were
also found to have greater amount of mindin protein in
their urine than their standard diet counterparts. In podocyte
cell culture, glucose administration was found to accentuate
mindin secretion. In humans with type II diabetes, the level
of urinary mindin was greater than that measured in healthy
controls, and the amount of urinary mindin increased in
concert with progression of diabetic nephropathy disease.
Thus, it can be appreciated that urinary mindin can function
as a biomarker of podocyte injury in diabetic nephropathy;
however, its general usage will be limited until further
investigations can determine its efficacy in this and other
glomerulopathies.
10. Alpha 3 Integrin (Int𝛼3)
Int𝛼3 is a heterodimeric, podocyte basal-membrane surface
protein that is responsible for the attachment of the foot
processes to the underlyingGBM.During renal development,
Int𝛼3 is necessary for normal organogenesis, for in mice
with amutated Itga3 gene abnormal collecting duct, proximal
tubule, and glomerular histology can be observed [24, 126].
The same mutated mice show a disrupted GBM and an
immature phenotype of podocytes lacking formation of foot
processes. Int𝛼3 is also shown to be necessary for normal pul-
monary organogenesis, with abnormal branching of bronchi
being observed. In patients found to be homozygous for
mutations in the gene encoding Int𝛼3, basement membrane
disruption was notable in numerous tissues and presented
clinically with congenital nephrotic syndrome, interstitial
lung disease, and epidermolysis bullosa [127]. Int𝛼3 is an
important contributor to the development and the mainte-
nance of the GBM-podocyte interaction.
Urinary Int𝛼3 has been examined to determine if it can
be utilized in the clinical setting as a biomarker of podocyte
injury. Data from an investigation examining Int𝛼3 as a
urinary biomarker for detecting the presence of varying
glomerular diseases concluded that it had a diagnostic sen-
sitivity of 18.6% and specificity of 100% [57]. The data from
this one reported study and a lack of any other investigations
do not support the utilization of Int𝛼3 as a diagnostic urinary
biomarker for glomerulopathies.
11. CD59
CD59 (also referred to as protectin or 20 kDa homologous
restriction factor—HRF20) is a glycosylphosphatidylinositol-
anchored membrane bound protein that regulates the for-
mation of the terminal complement complex of the immune
complement cascade [128]. Regulation of the formation of
the terminal complement complex is done so by the inhi-
bition of the binding of C9 to the C5b–C8 complex. In the
developing kidney, CD59 protein and mRNA are expressed
in the ureteric duct epithelium, while in the mature, adult
kidney expression they are found in the collecting ducts
[96]. CD59 immunofluorescent expression is also notable in
frozen sections of renal cortex—specifically in podocytes,
tubular epithelium, and endothelial cells—and in cultured
podocytes [129].The role of CD59 in renal development is not
clear, though it may act through inhibition of formation of
the terminal complement complexes which could otherwise
attenuate normal cellular growth. Regulation of the comple-
ment cascade within the glomerulus by CD59 is suggested
by its ability to inhibit the complement mediated immune
response to subepithelial immune complex deposition [130].
CD59 has not been utilized widely as a biomarker of
podocyte injury, but a single study did present data support-
ing further investigations. When the CD59 immunofluores-
cent expression in renal tissue samples from patients diag-
nosed with membranous glomerulonephritis was compared
to that in healthy controls, membranous glomerulonephritis
patients had lower CD59 expression [131]. CD59 concentra-
tion in the urine of patients with membranous glomeru-
lonephritis was higher in comparison to urinary CD59 from
healthy controls and patients with diabetic nephropathy. The
same investigation presented that urinaryCD59 levels did not
correlate to serum creatinine, urinary protein concentration,
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or duration of disease. With a paucity of data in hand,
conclusions on CD59’s usefulness as a histologic or urinary
biomarker of podocyte injury are constrained.
12. Wilms Tumor Protein 1 (WT1)
A podocyte transcription factor—WT1—can been found in
urine (associated with cells or exosomes) and as thus is a
novel biomarker for recognizing podocyte injury. As any
other typical transcription factor,WT1 activity is upregulated
by certain stimuli, and its activity is responsible for the
promotion of selective gene expression. WT1 regulates the
expression ofNphs1 and Podxl in mice, as both transcripts are
reduced in Wt1 knockouts [132]. In the same Wt1 knockout
mice, crescentic glomerulonephritis or mesangial sclerosis
can be observed. WT1 has been shown to directly bind to
the Podxl gene promoter, and through this mechanism it
influences expression [133]. WT1 is first noted in the C-
and S-shaped glomerular bodies of the developing kidney,
and in the mature kidney, WT1 can be found in glomerular
podocytes and arteriole endothelium [111]. WT1 is mutated
in patients with the Denys-Drash syndrome and the Frasier
syndrome, both which are present with nephrotic syndrome
and extra-renal malformations within the genital urinary
system [132]. It should be noted that while WT1 is a proven
histologic biomarker of podocytes [4, 118, 134], in a number
of glomerulopathies WT1 protein is immunohistochemically
expressed in glomerular parietal epithelium; therefore, WT1
as a biomarker of podocytesmay not be exclusive and specific
in diseased states [4, 135].
Urinary WT1 protein as a biomarker of podocyte injury
has been described in one study, and thus this is an initial
presentation of its utility. Data showed that by utilizing a
passive Heymann nephritis model, WT1 protein and Wt1
mRNA could be quantified from cells isolated from collected
urine samples [46]. Unfortunately with only one study in
hand, not much can be made in terms of deduction on the
efficacy of WT1 protein as a biomarker of podocyte injury;
however, investigation of WT1 from urinary exosomes shall
be discussed in the following section.
13. Podocyte Specific mRNA
Podocyte specific mRNA has been detected in urine, and
its usefulness as a biomarker of podocytopathy has been
described. Nephrin, podocin, synaptopodin, podocalyxin,
CD2AP, ACTN4 (encodes for 𝛼-actinin 4), PTPRO (encodes
for GLEPP-1), and WT1 mRNA have been isolated from
urine of patients with varying glomerulopathies. Review of
urinary nephrin, podocin, synaptopodin, podocalyxin, B7-
1, and PTPRO mRNA has already been described and can
be found in their respective sections above. CD2AP, ACTN4,
andWT1 urinary mRNA shall be discussed as follows.
Urinary WT1 protein and Wt1 mRNA expression were
observed and analyzed from cells isolated fromurine samples
of passive Heymann nephritic rats, and there was a concomi-
tant decrease in glomerular podocyte quantity as proteinuria
worsened [46]. This data would lend to the hypothesis that
glomerular podocytes in certain glomerulopathies are shed
and lost in the urine, and those podocytes in urine could
directly relate to the severity of podocyte/glomerular injury.
CD2AP and WT1 mRNA were found in urinary derived
podocytes of both FSGS patients and healthy humans;
therefore, quantitative analysis should be recommended in
determining if disease is present [45]. Urinary WT1 and
ACTN4 mRNA could also be collected from some dogs
and cats with chronic kidney disease, but this study did
not contain healthy control groups, so the significance of
these findings has yet to be determined [95]. Urinary CD2AP
and ACTN4 mRNA expression were significantly increased
in patients with diabetic nephropathy compared to healthy
controls, the level of mRNA increased with progression
of disease, and the levels of urinary CD2AP and ACTN4
mRNA positively correlated with levels of urinary albumin
excretion, BUN, and with serum creatinine [69]. With the
data presented in this and previous sections, along with the
fact that very little sample is necessary for the quantification
of mRNA transcript, there is promising evidence support-
ing podocyte specific urinary mRNA as a biomarker of
injury.
14. Exosomal Transcription Factor WT1
Exosomes are vesicles that can be attained from urine via
differential centrifugation, and they are excreted through the
length of the nephron, including from podocytes. Generally
they are found to be 50–100 nm in diameter and have
been seen to contain a number of cytosolic and membrane
proteins as shown with proteomic profiling [136]. The origin
of exosomes can be described as such: endocytic vesicles
fuse with multivesicular bodies, and thereafter multivesicu-
lar bodies can undergo invagination—taking into the new
vesicles matter that may be within the cytosolic milieu (e.g.,
WT1). At this stage, there is a multivesicular body that
contains vesicles, and at some point the multivesicular body
can fuse with the cellular plasma membrane and exocytose
the vesicles contained within it. Methods of urinary exosome
preparation and storage have been fine-tuned so that under
proper conditions the protein profile of exosomes remains
intact over time for analysis [137].
Data from one study presented that podocyte specific uri-
nary exosomes could be quantified from patients and animal
models of glomerulopathies: the podocyte specific aspect of
these exosomes as being the transcription factor WT1 [138].
In animal models for FSGS and collapsing glomerulopathy,
urinary exosomal WT1 quantity significantly increased after
insult, and in control animals urinary exosomal WT1 was
undetectable. Likewise, in human patients with diagnosed
FSGS urinary exosomal WT1 could be identified, while
exosomal WT1 couldnot be detected in the urine of healthy
volunteers. Thus, with the given data, urinary exosomal WT1
is specific for a diagnosis of glomerulopathy; however, more
work will have to be done to elaborate on the usefulness of
urinary exosomal WT1 as a biomarker of podocyte injury.
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15. Podocalyxin Positive Granular
Structures (PPGS)
Under microscopic examination of urine, granular struc-
tures can be identified, and if they are immunoreactive
for the podocyte specific antigen podocalyxin are termed
PPGS. PPGS have been proven to originate from podocytes
via podocalyxin immunostaining and are thought to form
through a process of tip vesiculation from microvillus for-
mations of injured podocytes. PPGS can be differentiated
from podocyte exosomes on three points: PPGS are found
not to contain exosomal specific markers (CD24 and CD63),
PPGS are larger than 100 nm in diameter (exosomes are
typically smaller), and in kidney samples from patients with
PPGS found in urine, histologic evidence of exocytosis—
the mechanism of by which exosomes are excreted—is not
prevalent [103, 139]. While PPGS are immunoreactive for
podocalyxin, there is weak staining against other podocyte
apical membrane specific proteins (GLEPP-1 and CR1), and
there was no observed staining against slit diaphragm specific
ZO-1 and podocyte basal membrane specific Int𝛼3 [103].
This further supports that PPGS originate from the apical
membrane of podocytes. It is also notable that urinary
supernatant has greater amount of podocalyxin protein than
urinary sediment (this is true for urine of both healthy
and patients with diagnosed glomerulopathies) and that
within the sediment PPGS are found within casts. Therefore,
quantification of PPGS from supernatant would be of higher
yield than from centrifuged urinary sediment. When urine
of patients with active glomerulonephritis and nephrotic
syndrome was compared to that from healthy controls,
greater amount of excreted PPGS could be observed in the
urine of diseased patients [139]. Healthy controls excreted low
levels of PPGS, and it may be explained by normal turnover
of podocytes. In glomerulonephritis patients (diagnosedwith
IgA nephropathy, Henoch-Scho¨nlein purpura nephritis, or
lupus nephritis) and patients with a diagnosis of nephrotic
syndrome, urinary sedimentary podocalyxin (which PPGS
was a constituent) was greater than in healthy controls, and
podocalyxin concentration was significantly greater in the
urinary sediment of glomerulonephritis patients than that of
the nephrotic patients [103]. PPGS could also be observed
in the urine of glomerulonephritis patients that did not
exhibit podocyturia, therefore showing that PPGS may be
more sensitive in detecting glomerulopathy and podocyte
injury [57]. The described data shows that PPGS are a more
focused biomarker than general podocalyxin in the urine—
keeping inmind that podocalyxinmay be present in the urine
additionally in association with whole podocytes. Utilization
of PPGS as a biomarker of podocyte injury seems promising;
however, as with all of the discussed biomarkers above,
thorough clinical studies it would be needed to strengthen the
argument for its clinical usage.
16. Conclusion
It has been found that podocyte injury can be diagnosed
and monitored through the utilization of urinary derived
biomarkers. The findings that podocalyxin and nephrin
proteins can be detected in the urine of a significant per-
centage of normoalbuminuric, diabetic patients highlight the
screening utility that these two podocyte specific proteins
carry. Since monitoring urinary albumin potentially results
in the passing over of a significant segment of diabetic
patients—a fraction of today’s population that cannot be
dismissed—the medical field may wish to examine closely
the earlier detection of diabetic nephropathy garnered from
utilizing a podocyte specific marker. One could also mon-
itor glomerulopathy progression with a urinary derived
biomarker, diverting the need for follow-up renal biopsy if
the patient was not physiologically stable or did not desire
for such a procedure. Monitoring urinary biomarkers of
podocyte injury also holds the capacity to be a cheaper
method of diagnosis than the renal biopsy—a concept that
we cannot ignore as the financial environment pressures the
budget of healthcare. With respect to other biomarkers used
in clinical practice, urinary biomarkers could be utilized
in such manners as supplemental evidence of disease (as
troponins are used alongside electrocardiography to aid in
the diagnosis of myocardial infarction) or for the monitoring
of disease progressionwith analysis of therapeutic efficacy (as
hemoglobin A1C is used in patients with diabetes mellitus).
The strength of urinary podocyte biomarkers in clinical
utility would be measured the best in their combination with
the clinical picture of the patient and other determinants of
renal function, and theymost likely will not themselves usurp
the quantification of proteinuria as a measure of glomerular
function. The utilization of the podocyte specific urinary
biomarkers has not yet translated into common clinical
practice, while the age-old quantification of proteinuria and
renal biopsy are the mainstays that clinicians have at hand
and will probably continue to rely on. However, with further
investigations of the podocyte biomarkers discussed this
stance could change, and attest to their utility. The reader
is referred to Table 1 as a synoptic of the discussed urinary
biomarkers and their prognostic correlation to specifically
studied glomerulopathies.
By definition, a biomarker is any parameter of a
patient/animal model that can be quantified, and through
its quantification a normal physiologic state, a pathologic
state, or disease response to initiated therapy can be indicated
[140]. Before any of the described urinary biomarkers of
podocyte injury can be used in the clinical setting, they
should express a number of characteristics. Characteristics of
a renal biomarker satisfactory for regular usagewould include
the following: that its quantification is simple, accurate, and
reproducible; it is a sensitive indicator of kidney injury
or a sensitive indicator of disease response to treatment;
it gives clinicians a budget-sensitive tool; it provides the
clinician additional information not yet attained by other
tests/examinations; it diagnoses and differentiates between
renal pathologies; it is clinically applicable in differing
demographics [38, 141]. Since the classic monitoring of
proteinuria/albuminuria does not meet all of the described
characteristics of an ideal biomarker, possibly the novel
biomarkers in this paper may complement data gleaned
from such conventional tests and provide the clinician more
information on the presence of a glomerulopathy.
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Table 1: Urinary biomarkers of podocytopathy in patients: increased urinary levels correlate with the presence or the advancement of
glomerular disease (except when otherwise noted∗).
Protein mRNA Exosomal transcriptionfactor PPGS
Podocalyxin
IgAN [55, 56, 60, 61]
HSPN [55, 56]
DN [58, 67]
FSGS—increased u-podocalyxin
correlates with better prognosis
[62]∗
AKI—increased u-podocalyxin
in recovering patients [66]∗
PE [65]
Podocalyxin DN [69] WT1 FSGS[138]
AcGN
[139]
NS
[103, 139]
IgAN [103]
HSPN
[103]
LN [103]
Nephrin DN [77, 78]PE [65, 80] Nephrin
DN [87, 89]
PE [91]
FSGS [90]
LN [86, 88]
IgAN [89]
MCD [89]
MN [89]
Podocin PE [64] Podocin
PE [91]
DN [69, 89]
IgAN [89]
MCD [89]
MN [89]
LN [85] and—decrease in
u-podocin mRNA follows
decrease in GFR [88]∗
CR1
AuGN [103]
NS [103]
LN [57] and—lower u-CR1 in
advanced cases [102]∗
MN [57]
MPGN [57]
AS [57]
PSAGN [57]
HSPN [57]
IgAN [57]
CD2AP DN [69]
CD80 Relapsed MCD [104] B7-1a FSGS [90]
Mindin DN [123] Synaptopodin
DN [69, 87, 113]
LN—decrease of
u-synaptopodin mRNA
follows decrease in GFR [88]∗
CD59 MG [131] ACTN4b DN [69]
Numbers in parentheses refer to citations that can be noted in the References section of this paper.
Abbreviations: messenger ribonucleic acid (mRNA), complement receptor 1 (CR1), Wilms tumor protein 1 (WT1), CD-2-associated protein (CD2AP),
podocalyxin positive granular structures (PPGS), urinary podocalyxin (u-podocalyxin), urinary CR1 (u-CR1), urinary podocin mRNA (u-podocin mRNA),
urinary synaptopodin mRNA (u-synaptopodin mRNA), IgA nephropathy (IgAN), Henoch-Scho¨nlein purpura nephritis (HSPN), diabetic nephropathy
(DN), focal segmental glomerulosclerosis (FSGS), acute kidney injury (AKI), preeclampsia (PE), lupus nephritis (LN), minimal change disease (MCD),
membranous nephropathy (MN), nephrotic syndrome (NS), acute glomerulonephritis (AuGN), active glomerulonephritis (AcGN), membranoproliferative
glomerulonephritis (MPGN), Alport syndrome (AS), and poststreptococcal acute glomerulonephritis (PSAGN).
∗This table summarizes that the majority of studies presented direct correlation of increased urinary levels of a biomarker with the incident or worsening of a
specific glomerular disease; however, some studies (as noted with an asterisk and a short explanation) presented opposite findings and are thus highlighted.
aB7-1 encodes for CD80.
bACTN4 encodes for 𝛼-actinin 4.
It is also obvious from this review of the literature that
more work will be needed to determine if the discussed
urinary biomarkers of podocyte injury are suitable for clinical
use. In addition for the need for further investigation of
the already mentioned biomarkers, there are other possible
podocyte specific biomarkers that could be quantified in
urine. For example, neurexin-1 is a slit diaphragm protein
that also has indirect interaction with the podocyte actin
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cytoskeleton and therefore may be influential in regulating
both podocyte function and architecture [142, 143]. Another
potential candidate for usage as a urinary biomarker of
podocyte injury is myosin heavy chain 9 (MYH9), which
is a subunit of a larger protein named nonmuscle myosin
IIA [8]. Mutation in the gene that encodes for MYH9 is
found to be responsible for Fechtner’s syndrome, and in
addition, MYH9 has been identified in urine samples [136,
144]. There are potentially other components of podocytes
that could be identified in the urine of patients afflicted
with glomerulopathies useful as biomarkers, and as such
this provides a number of possible routes of investigation to
follow.
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